Liz Highleyman
Published: 16 May 2013
Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained viral response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the 48th International Liver Congress (EASL 2013) last month in Amsterdam.
While many hepatitis C patients await interferon-free direct-acting antiviral regimens, others have advanced liver disease and need treatment now. This group includes liver transplant recipients, as HCV almost always recurs and infects the new liver in the absence of treatment
No comments:
Post a Comment